292 related articles for article (PubMed ID: 12930575)
1. Luteinizing hormone affects uterine receptivity independently of ovarian function.
Tesarik J; Hazout A; Mendoza C
Reprod Biomed Online; 2003; 7(1):59-64. PubMed ID: 12930575
[TBL] [Abstract][Full Text] [Related]
2. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
3. Ovarian responses to recombinant FSH or HMG in normogonadotrophic women following pituitary desensitization by a depot GnRH agonist for assisted reproduction.
Balasch J; Peñarrubia J; Fábregues F; Vidal E; Casamitjana R; Manau D; Carmona F; Creus M; Vanrell JA
Reprod Biomed Online; 2003; 7(1):35-42. PubMed ID: 12930572
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). The ganirelix dose-finding study group.
Hum Reprod; 1998 Nov; 13(11):3023-31. PubMed ID: 9853849
[TBL] [Abstract][Full Text] [Related]
5. An artificially induced follicle stimulating hormone surge at the time of human chorionic gonadotrophin administration in controlled ovarian stimulation cycles has no effect on cumulus expansion, fertilization rate, embryo quality and implantation rate.
Vermeiden JP; Roseboom TJ; Goverde AJ; Suchartwatnachai C; Schoute E; Braat DD; Schats R
Hum Reprod; 1997 Jul; 12(7):1399-402. PubMed ID: 9262265
[TBL] [Abstract][Full Text] [Related]
6. Too much of a good thing? Experimental evidence suggests prolonged exposure to hCG is detrimental to endometrial receptivity.
Evans J; Salamonsen LA
Hum Reprod; 2013 Jun; 28(6):1610-9. PubMed ID: 23515188
[TBL] [Abstract][Full Text] [Related]
7. [Medroxyprogesteron acetate use to block LH surge in oocyte donor stimulation].
Crha I; Ventruba P; Filipinská E; Dziakova M; Žáková J; Ješeta M; Lousová E; Papíková Z
Ceska Gynekol; 2018; 83(1):11-16. PubMed ID: 29510633
[TBL] [Abstract][Full Text] [Related]
8. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
Gerris J; De Vits A; Joostens M; Van Royen E
Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
[TBL] [Abstract][Full Text] [Related]
9. Effects of exogenous LH administration during ovarian stimulation of pituitary down-regulated young oocyte donors on oocyte yield and developmental competence.
Tesarik J; Mendoza C
Hum Reprod; 2002 Dec; 17(12):3129-37. PubMed ID: 12456612
[TBL] [Abstract][Full Text] [Related]
10. Mifepristone is an effective oral alternative for the prevention of premature luteinizing hormone surges and/or premature luteinization in women undergoing controlled ovarian hyperstimulation for in vitro fertilization.
Escudero EL; Boerrigter PJ; Bennink HJ; Epifanio R; Horcajadas JA; Olivennes F; Pellicer A; Simón C
J Clin Endocrinol Metab; 2005 Apr; 90(4):2081-8. PubMed ID: 15483085
[TBL] [Abstract][Full Text] [Related]
11. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
[TBL] [Abstract][Full Text] [Related]
12. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
[TBL] [Abstract][Full Text] [Related]
13. [Correlation between serum inhibin B level after treatment with gonadotropin releasing hormone agonist and outcome of in vitro fertilization-embryo transfer].
Lin WQ; Yang HY; Lin JJ; Chen X; Ye BL
Zhonghua Fu Chan Ke Za Zhi; 2009 Apr; 44(4):260-2. PubMed ID: 19570462
[TBL] [Abstract][Full Text] [Related]
14. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
[TBL] [Abstract][Full Text] [Related]
15. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
[TBL] [Abstract][Full Text] [Related]
16. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
17. Intrauterine human chorionic gonadotropin infusion in oocyte donors promotes endometrial synchrony and induction of early decidual markers for stromal survival: a randomized clinical trial.
Strug MR; Su R; Young JE; Dodds WG; Shavell VI; Díaz-Gimeno P; Ruíz-Alonso M; Simón C; Lessey BA; Leach RE; Fazleabas AT
Hum Reprod; 2016 Jul; 31(7):1552-61. PubMed ID: 27122490
[TBL] [Abstract][Full Text] [Related]
18. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles.
Simon C; Oberyé J; Bellver J; Vidal C; Bosch E; Horcajadas JA; Murphy C; Adams S; Riesewijk A; Mannaerts B; Pellicer A
Hum Reprod; 2005 Dec; 20(12):3318-27. PubMed ID: 16085660
[TBL] [Abstract][Full Text] [Related]
19. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone.
Fleming R; Lloyd F; Herbert M; Fenwick J; Griffiths T; Murdoch A
Hum Reprod; 1998 Jul; 13(7):1788-92. PubMed ID: 9740424
[TBL] [Abstract][Full Text] [Related]
20. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
